New LaunchJun 1, 2026, 07:32 AM
Cytokinetics Launches MYQORZO in Germany for oHCM Treatment
AI Summary
Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. This follows the European Commission approval in February 2026, which was based on positive results from the pivotal Phase 3 SEQUOIA-HCM clinical trial. MYQORZO was previously approved in December 2025 by the U.S. FDA and the China National Medical Products Administration (NMPA), marking a significant global expansion for the company's cardiac myosin inhibitor.
Key Highlights
- MYQORZO (aficamten) commercially launched in Germany for symptomatic oHCM.
- European Commission approved MYQORZO in February 2026.
- U.S. FDA approved MYQORZO in December 2025 for oHCM.
- China NMPA also approved MYQORZO for oHCM treatment.
- Phase 3 SEQUOIA-HCM trial showed pVO2 increase of 1.76 mL/kg/min vs. 0.0 mL/kg/min for placebo.
- Statistically significant (p<0.0001) improvements in all 10 secondary endpoints.
Price Impact
More from CYTK